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Abstract
Reporter gene (RG) imaging of cell-based therapies provides a direct readout of therapeutic efficacy by assessing the fate of
implanted cells. To permit long-term cellular imaging, RGs are traditionally required to be integrated into the cellular
genome. This poses a potential safety risk and regulatory bottleneck for clinical translation as integration can lead to cellular
transformation. To address this issue, we have developed non-integrative, replicating minicircles (MCs) as an alternative
platform for safer monitoring of cells in living subjects. We developed both plasmids and minicircles containing the scaffold/
matrix attachment regions (S/MAR) of the human interferon-beta gene, driven by the CMV promoter, and expressing the
bioluminescence RG firefly luciferase. Constructs were transfected into breast cancer cells, and expanded S/MAR minicircle
clones showed luciferase signal for greater than 3 months in culture and minicircles remained as episomes. Importantly,
luciferase activity in clonal populations was slowly lost over time and this corresponded to a loss of episome, providing a
way to reversibly label cells. To monitor cell proliferation in vivo, 1.56106 cells carrying the S/MAR minicircle were implanted
subcutaneously into mice (n = 5) and as tumors developed significantly more bioluminescence signal was noted at day 35
and 43 compared to day 7 post-implant (p,0.05). To our knowledge, this is the first work examining the use of episomal,
self-limited, replicating minicircles to track the proliferation of cells using non-invasive imaging in living subjects. Continued
development of S/MAR minicircles will provide a broadly applicable vector platform amenable with any of the numerous RG
technologies available to allow therapeutic cell fate to be assessed in individual patients, and to achieve this without the
need to manipulate the cell’s genome so that safety concerns are minimized. This will lead to safe tools to assess treatment
response at earlier time points and improve the precision of cell-based therapies.
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Introduction
Cell-based therapies have emerged as novel therapeutics for the
treatment of a variety of diseases including cancer, cardiovascular
and neurodegenerative diseases. Promising examples include
adoptive immunotherapy for cancer treatment [1] and stem cell
therapy for the regeneration of ischemic heart disease [2].
Unfortunately, traditional readouts of treatment success are often
indirect (e.g., tumor shrinkage) and only assessable long after cell
delivery, making timely adjustment of treatment course difficult
[3]. Direct, repeatable monitoring of the fate of delivered cells will
allow therapeutic efficacy to be assessed at earlier time points,
improve the ability to identify responders and non-responders, and
overall, allow more precise cell-based therapies to become a
reality.
Non-invasive imaging of therapeutic cells is the most promising
approach for monitoring cell fate. In particular, imaging strategies
using reporter genes (RGs) can provide information of the
location(s), number, viability and differentiation status of delivered
cells. Many RG technologies have been developed in the last few
decades for imaging modalities such as fluorescence (FL) [4] and
bioluminescence (BLI) imaging [5,6], magnetic resonance imaging
(MRI) [7], positron emission tomography (PET) [8], and for
emerging technologies such as photoacoustic imaging [9]. Despite
these tremendous advances only a single study has translated one
of these RG technologies into tracking of therapeutic cells in
patients [10]. One of the main reasons for this is potential safety
concerns regarding the genetic modification of cells using
integrating vectors that have the potential to cause insertional
mutagenesis and malignant transformation of cells. This concern
has been known for a long time but has become a reality ever since
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2 male patients treated with integrating retroviruses developed T-
cell acute leukemia-like syndrome during a gene therapy trial to
treat X-linked severe combined immunodeficiency disease (SCID-
X1) [11,12]. In order to avoid this serious issue and safely track
proliferating cells in humans, non-integrative (episomal) vector
platforms with autonomous replicative capability would have
significant potential.
In the past decade several groups have reported the develop-
ment of non-viral vectors containing the human interferon-beta
(hIFN-ß) scaffold/matrix attachment region (S/MAR) [13–16].
Once introduced into cells in culture, S/MAR vectors remain
episomal and can recruit host replication machinery to promote
vector replication once per cell cycle [17]. Over time, optimization
of S/MAR vectors has been achieved with several groups showing
that removal of prokaryotic sequences to generate S/MAR
minicircles (MCs) allows dividing cells to be labeled for several
generations without the need for antibiotic selection and with
minimal integration events [14–16]. While the episomal nature
and replicative ability of S/MAR constructs has been established
in both cultured cells [13–16] and transgenic pig fetuses [18], the
ability of these constructs to replicate when delivered to tissues in
vivo (without some form of selection advantage [19]) has been
difficult [16]. Despite these challenges for their use as gene therapy
vehicles, we were inspired by the results shown in cultured cells
using S/MAR MCs and hypothesized that this technology could
be extended beyond the culture dish and be used to safely track
transplanted RG labeled cells in living subjects.
Therefore, our objectives in this study were: 1) to develop S/
MARMCs that expressed a bioluminescence RG to allow dividing
cells to be imaged both in culture and in living mice; 2) to show
that these constructs would express transgenes and remain
episomal for extended periods of time in culture; and 3) to
investigate whether RG labeled cultured cells could be transplant-
ed into animals and their proliferation and viability could be
monitored over time with non-invasive imaging. To our knowl-
edge, this is the first work demonstrating the ability to track cells in
living subjects using replicating episomal MCs and lays the
foundation for future vectors expressing clinically relevant RGs for
imaging modalities such as PET or MRI, so that therapeutic cells
can be tracked in patients.
Materials and Methods
Ethics Statement
The Administrative Panel on Laboratory Animal Care at
Stanford University approved all animal experiments and all
efforts were made to minimize animal suffering.
Vector Construction
The construct pEPI-eGFP was kindly provided by Dr. Hans
Lipps [18]. This plasmid is driven by the CMV promoter (pCMV),
expresses enhanced green fluorescent protein (eGFP), and contains
the S/MAR region from the human IFN-ß gene (,2.0 kb) directly
downstream of eGFP. We replaced eGFP with the codon-
optimized bioluminescence reporter gene firefly luciferase (Luc2)
to generate pEPI-Luc2. Next, to generate both parental plasmids
(PP) and MCs we used the system described by Kay et al [20]
(System Biosciences, Mountain View, CA). Briefly, we subcloned
the pCMV-Luc2-S/MAR transcription unit out of pEPI-Luc2 and
into the MN-100 PP backbone (System Biosciences, Mountain
View, CA) containing an SV40 polyA sequence to generate PP-
pCMV-Luc2-S/MAR (Figure 1A - top). Both PP-pCMV-Luc2-S/
MAR (PP) and MC-pCMV-Luc2-S/MAR (Figure 1A - bottom)
were amplified and purified according to the protocol outlined in
Kay et al [20] and the supplier’s instructions (System Biosciences,
Mountain View, CA). Briefly, ZYCY10P3S2T E. coli were
transformed with the PP, colonies were picked and E. coli were
grown overnight in TB broth. To generate MCs, site-specific
recombination via expression of phiC31 integrase was initiated by
addition of equal volume of LB broth containing 0.001% L-
arabinose and 16 mL NaOH, and cultures were grown for an
additional 5.5 hours at 30uC. For the PP, the cells were grown in
the same media without L-arabinose supplementation. Endotoxin-
free mega kits (Qiagen, Valencia, CA) were used to purify both PP
and MC.
Cell Transfection and BLI in Cell Culture
MDA-MB-231 human breast cancer cells (ATCC, Manassas,
VA) were grown in DMEM high glucose medium (Gibco,
Carlsbad, CA) supplemented with 10% Fetal Bovine Serum
(FBS), and 1% Penicillin/Streptomycin (P/S) solution. For
transfection, 2.56104 cells were plated in 24-well plates and
transfected with both PP and MC at equal mass (1 mg) using a
linear polyethylenimine transfection agent (jetPEI, Polyplus
transfection, Illkirch, France) according to the manufacturer’s
instructions. After reaching confluency, cells were transferred to
10 cm plates and bioluminescence imaging was performed to
detect firefly luciferase (Fluc) activity using a Xenogen IVIS 50
imaging system (Caliper Life Sciences, Waltham, MA) 5 minutes
after addition of D-Luciferin (0.03 mg/ml) at 37uC.
Luminometer Assay
Cells were lysed in 16Passive lysis buffer (Promega, Sunnyvale,
CA) for 15 minutes on ice and lysate was centrifuged at
14,000 rpm for 5 minutes at 4uC. Supernatant was collected
and Fluc activity was determined using 10 mL lysate after addition
of 100 mL LAR-II substrate (Promega, Sunnyvale, CA) in a TD
20/20 luminometer (Turner Designs, Sunnyvale, CA). An
integration time of 10 seconds was used for all measurements
recorded as relative light units (RLU). The protein content (mg) of
tissue lysates was determined using a Pierce 660 nm Protein Assay
system (Thermo Scientific, Rockford, IL) in a BioTek Synergy 4
microplate reader (BioTek Instruments, Winooski, VT). Normal-
ized Fluc activity is reported as RLU per mg of protein.
Southern blot analysis
Total DNA was isolated from MDA-MB-231 cells using the
DNeasy Blood and Tissue Kit according the manufacturer’s
instructions (Qiagen, Valencia, CA). DNA concentration was
quantified using a Nanodrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE). Total DNA was digested with a single
cutting restriction enzyme (EcoRI), and 40 mg was separated on a
0.7% agarose gel (30 V, 20 mA for 7 hours). DNA was then
blotted overnight onto Amersham Hybond-N+ paper according to
the manufacturer’s instruction (GE Healthcare, Buckinghamshire,
UK). Finally, a 400 bp Luc2 probe was labeled with alkaline
phosphatase using the Amersham Gene Images AlkPhos Direct
Labelling and Detection System (GE Healthcare, Buckingham-
shire, UK), and chemiluminescent signal detection was performed
as per the manufacturer’s instructions.
Tumor Development and In Vivo BLI
To perform in vivo imaging of cell proliferation, 1.56106 cells
from a S/MAR MC clonal population (clone 3–7; 61 days post-
transfection) were implanted subcutaneously into the right flank of
Nu/Nu mice (n = 5). BLI was performed on days 7, 20, 28, 35, and
43 post-implantation using a Xenogen IVIS Spectrum imaging
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system (Caliper Life Sciences, Waltham, MA). Each mouse was
injected intraperitoneally with 100 mL of D-Luciferin (30 mg/mL)
and a series of images was collected between 5 and 20 minutes
post-injection. A region of interest was drawn over the tumor in
each image and the peak average radiance (photons/sec/cm2/
steradian) within the imaging period was measured.
Statistics
To compare normalized Fluc activity in cultures at days 64 and
121 we performed a paired two-tailed t-test. To compare average
radiance measurements taken over time we performed a repeated
measures analysis of variance followed by a Tukey’s post-hoc test.
A nominal p-value less than 0.05 was considered to be significant.
Results
S/MAR MCs can label cells with RGs for extended periods
of time in culture and remain episomal
We developed both parental plasmids (PPs) and minicircles
(MCs) driven by the CMV promoter, expressing a firefly luciferase
gene (Luc2), and containing the hIFN-ß S/MAR (pCMV-Luc2-S/
MAR; Figure 1A). The PP was approximately 8.5 kb in size,
whereas after removal of prokaryotic components the MC was
about 4.5 kb (Figure 1B). As previously described [16], the stress
induced duplex destabilization (SIDD) profile of the MC (at a
superhelical density of -0.05) revealed regular intervals within the
S/MAR motif with low denaturation energy (G(x)), demonstrating
a high propensity for this region to undergo strand separation
(http://benham.genomecenter.ucdavis.edu/; Figure 1C). The PP
also showed a similar pattern within the S/MAR region (data not
shown).
Our first experimental objective was to establish the ability of
our S/MAR MCs to label cultured cells with RGs for extended
periods of time. MDA-MB-231 breast cancer cells were transfected
with either PP or MC, grown without antibiotic selection, and
imaged at both day 6 and 9 after transfection (Figure 2A). Unlike
S/MAR PPs, S/MAR MCs do not require antibiotic selection to
become established as replicating episomes. Therefore we expect
that luciferase activity will be lost over time using S/MAR PPs but
better maintained with S/MAR MCs. Cells were transfected with
equal mass of PP and MC and therefore due to the inherent
differences in transfection efficiencies we focused our comparisons
of relative Fluc levels over time to changes within rather than
between PP and MC cell populations. On day 6, both PP and MC
showed strong bioluminescent signal. In contrast, at day 9, after
several days of continued cell growth, the MC signal began to
show foci of strong luminescent signal, whereas the PP signal
began to disappear (Figure 2A). At this point individual S/MAR
MC cell colonies that displayed high levels of bioluminescent
signal were isolated and expanded to generate clonal cell
populations. Several of these clones (clone 2-1, 3-5, and 3-7) were
maintained in culture for extended periods of time (,4 months)
and serial BLI was performed (Figure 2B). As seen in Figure 2B,
each clone continued to display bioluminescent signal for at least 3
months following transfection, indicating the ability to express RG
in cells with S/MAR MCs for extended periods of time.
We next isolated total DNA from both control cells and one of
our S/MAR MC clones (clone 3-7) and determined whether the
Figure 1. Design and construction of self-replicating minicircle constructs. A) Vector maps of both parental plasmid (PP; top) and minicircle
(MC; bottom) versions of pCMV-Luc2-S/MAR. B) Agarose gel electrophoresis analysis confirming the ability to generate both PP (8.5 kb) and MC
(4.5 kb). C) Stress induced duplex destabilization (SIDD) profile of MC-pCMV-Luc2-S/MAR at a standard superhelical density of20.05. Note the regular
low denaturation energies (G(x)) between base pairs 2332 and 4314 corresponding to the location of the S/MAR motif.
doi:10.1371/journal.pone.0073138.g001
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construct existed as an episome by performing Southern blot
analysis. After digesting total DNA with a single restriction enzyme
(EcoRI) to linearize the MC and hybridizing with a Luc2 probe,
we were able to detect a single band in our S/MAR MC clonal
population at day 47 post-transfection (Figure 2C). Importantly
this band showed up at the correct size for our S/MAR MC
construct (4.5 kb), as was also shown for control DNA spiked with
our S/MAR MC construct. No band was detectable in DNA from
control cells (Figure 2C). Therefore, similar to previous studies
[14–16], this confirms that our S/MAR MC construct exists as an
episome and can replicate autonomously as cells divide.
Both RG expression and episomes are slowly lost in S/
MARMC labeled cellsWhile we detected luminescent signal in
the culture dish over time, the results in Figure 2B do not reflect
differences in the number of cells in each dish at the time of
imaging. Therefore, we performed a luminometer assay and
protein assay on lysates from S/MAR MC clonal populations to
measure Fluc activity (relative light units; RLU) normalized to
protein content (mg) (Figure 3A). Comparing results at days 64 and
Figure 2. S/MAR MCs can label cells in culture for extended periods of time and remain episomal. A) pCMV-Luc2-S/MAR PP and MC
constructs were transfected into MDA-MB-231 cells, grown in the absence of antibiotic selection, and BLI was performed over the course of 9 days.
On day 6, both MC and PP showed strong BLI signal within the cells. However, by day 9, the MC-labeled cells continued to display strong signal and
the signal from PP-labeled cells began to disappear. On this day MC-labeled clones displaying strong luminescent signal were isolated and expanded.
B) Two clones (3–5 and 3–7) were cultured over the course of 91 days post-transfection and continued to be imaged. Both clones continued to show
luminescent signal over the entire 3-month period. C) Southern blot analysis was performed on total DNA isolated from control cells, from control
cells spiked with 200 pg of S/MAR MC, and from an S/MAR MC clonal population (clone 3-7) 47 days after transfection. Total DNA (40 mg) was
digested with a single cutting enzyme and probed with a Luc2 probe. A single band at the correct size (4.5 kb) was detectable only in the lanes with
control DNA spiked with the original construct (lane 1) and the S/MAR MC clone (lane 3), confirming the episomal nature of the construct.
doi:10.1371/journal.pone.0073138.g002
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121 post-transfection across the three S/MAR MC clones we
noted a trend (p = 0.18) towards decreased normalized Fluc
activity (64% decrease for clone 3-7, 86% decrease for clone 3-5,
and 87% decrease for clone 2-1), signifying a slow loss of Fluc
activity over time. For S/MAR clone 3-7, which showed the
highest Fluc activity of all clones and was cultured for the longest
period of time, Fluc activity continued to decline up to day 178
post-transfection (97% decrease compared to day 64).
We then wanted to investigate whether this slow loss in Fluc
activity corresponded to a decrease in S/MAR MC episomal
content as assessed by Southern blot (Figure 3B). At day 64, as at
day 47 in Figure 2C, we saw a clear single band indicating a
significant number of episomes in this clonal population (clone 3-
7). In contrast, at day 121 a band was barely discernible
demonstrating that the S/MAR MC was slowly lost over time.
Therefore, our results show that over long periods of time in
culture labeling of cells with S/MAR MCs driven by the CMV
promoter, results in a decreasing percentile of MC positive cells
over time, and appears to be intrinsically reversible.
S/MAR MC labeled cells can be implanted into small
animals and cell proliferation can be monitored over
time with non-invasive imaging
To show that S/MAR MCs can be used as a platform for
tracking proliferating cells in vivo we implanted 1.56106 MDA-
MB-231 Luc2-S/MAR MC labeled cells (clone 3-7; day 61 post-
transfection) into the right flank of 6 week old female Nu/Nu mice
and performed BLI over time (Figure 4 and Figure S1). As shown
in Figure 4A, as tumors developed we saw an increase in the
bioluminescent signal in the flank of these animals. We confirmed
this observation by quantifying the amount of bioluminescent
signal emanating from tumors. To do this, we performed ROI
analysis over tumor sites and detected significant increases in
average radiance at days 35 and 43 post-implantation compared
to day 7. (Figure 4B). Therefore, as cells divided in vivo the S/MAR
MCs continued to replicate, verifying that these constructs can be
used to perform RG imaging of dividing cells in living subjects.
Discussion
Many cell-based therapies are rapidly being developed for the
treatment of a variety of devastating diseases. Direct imaging of
cell fate has tremendous potential to improve the ability to assess
therapeutic efficacy in individual patients. However, safety
concerns regarding integrative technologies needed to genetically
modify cells often represents a significant regulatory bottleneck
that limits widespread adoption of RG technology into cell therapy
trials. In this study, we showed that S/MAR MCs can be used to
label cells in culture with imaging RGs over extended periods of
time and that these constructs remain episomal within the cells.
Unexpectedly but importantly, we also show evidence that with
our S/MAR MC constructs RG expression is slowly lost over
extended periods of time in culture and that this corresponds to a
slow loss of S/MAR MCs. Lastly, we demonstrated the ability to
implant cells labeled in culture into living subjects and to monitor
in vivo cell proliferation and viability over extended periods of time
(.40 days).
Two main cellular imaging approaches have been established.
The first involves the labeling of cultured cells with imaging small
molecules or nanoparticles followed by imaging of implanted cells
in vivo. One of the main drawbacks of this technique are that as
cells divide the imaging labels get diluted, making it difficult to
track cells over extended periods of time and to quantify cell
numbers. Furthermore, if a cell dies the label will still persist for
some time and so false-positive cell imaging results are likely. The
second method involves labeling of cultured cells with imaging
RGs followed again by imaging of implanted cells in living
subjects. The RG either intrinsically produces imaging signal such
as fluorescent proteins [4] and some MRI reporter genes [21,22],
or expresses a protein that traps a systemically administered
reporter probe (RP) such as BLI or PET RG/RP systems [5,6] [8].
Importantly, no dilution of imaging signal is seen during cell
division since each daughter cell receives a new copy of the RG,
and critically, dead cells also no longer express the RG, allowing
cell viability to be assessed. This makes RGs the ideal cell tracking
Figure 3. Luciferase activity and S/MAR MCs are slowly lost over time in labeled cell populations. A) Normalized luciferase expression
was measured at both day 64 and 121 post-transfection in three S/MAR MC clonal populations. All clones showed a trend (p = 0.18) towards
decreased normalized luciferase expression over long periods of time in culture. S/MAR clone 3-7 was cultured up to day 178 after transfection and
continued to show a slow loss of luciferase activity. B) The decrease in luciferase expression corresponded to a decrease in Luc2-S/MAR MC as shown
via Southern blot analysis. A single band was seen in both control DNA spiked with 100 pg of S/MAR MC and DNA from S/MAR MC clone 3-7 at day
64 post-transfection. However, a band is barely discernable at day 121 from S/MAR MC clone 3-7, indicating a slow loss of S/MAR MC over time.
doi:10.1371/journal.pone.0073138.g003
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technology, however until now the main drawback of RGs is the
need to genetically modify the cells one wants to track.
Traditionally, cells that stably express RGs are modified using
either viruses (e.g., lentiviruses) that readily, but randomly,
integrate their genetic content into the genome [2,23], or with
plasmids followed by antibiotic selection [10], which also results in
random integration into the genome. Dependent on where these
integrations occur, these technologies can ultimately cause
deregulation of endogenous genes. This may have important
consequences on both the normal biological function of the cells
[24,25], or more importantly may activate nearby proto-
oncogenes, transforming the therapeutic cell one wants to label
into a malignant cell [11,12]. Hence, if possible, these random
integration technologies should be avoided and alternative vector
platforms should be explored. In two very recent studies, site-
directed integration of RGs into stem cells using either phiC31
integrases [26] or zinc-finger nucleases [27] has been explored as
an alternative to random integrative technologies. These are
exciting and promising ways to avoid critical sites within the
genome associated with proto-oncogene activation and insert
foreign genetic material into so-called genomic ‘‘safe harbours’’.
However, one caveat to this strategy is that this still requires
genetic modification of the genome. Considering that the latest
evidence (ENCODE project) ascribes approximately 80% of the
genome with transcribed functional elements, both coding and
non-coding RNAs, and 99% of the genome lies within 1.7 kb of a
biochemical event [28], we believe an episomal technology that
avoids integration altogether will be preferred from both
functional and safety perspectives.
There are 3 examples of replicating episomal vector systems
used to modify cells [29]. These include human artificial
chromosomes (HACs), vectors composed of viral replication
origins and trans-activating factors, and S/MAR vectors. The
former two vector classes have their drawbacks. The major
limitations of HACs relate to complexity of production and the
difficulty to efficiently deliver these large vectors into target cells
[29]. Alternatively, all known viral-based vectors rely on the
expression of proteins known to induce cellular transformation,
such as Epstein-Barr virus nuclear antigen 1 (EBNA-1) [30], and
so it is unlikely that this vector class will have any clinical utility. In
contrast, S/MAR MCs are easy to construct, can be readily
introduced into cells, and exploit human chromosomal elements to
induce replication and maintenance in progeny cells. Therefore, of
the three vector platforms described to date, S/MAR vectors are
arguably the most promising in terms of ease of use, safety, and
clinical translatability.
The first S/MAR vector to be described, called pEPI-1, was a
plasmid containing the hIFN-ß S/MAR and the SV40 origin of
replication (ORI) [13]. This vector was shown to maintain mitotic
stability by binding to matrix proteins such as SAF-A (also known
as hnRNP-U)[31] and replicate episomally once-per-cell-cycle in a
semiconservative fashion [13,32]. Later it was shown that
constructs containing a transcription unit linked to a downstream
S/MAR (i.e. without an SV40 ORI) was sufficient for mainte-
Figure 4. Proliferation of S/MAR MC labeled cells can be monitored over time in living subjects. A) S/MAR MC labeled breast cancer cells
were implanted into the right flank of Nu/Nu mice and bioluminescence imaging (BLI) was performed over time. As tumors developed more
luminescent signal was noted. B) This observation was confirmed by performing region of interest analysis over the tumor and measuring average
radiance (p/s/cm2/sr) at days 7, 20, 28, 35 and 43 post-implantation. Significantly higher BLI signal (n = 5; * p,0.05) was noted at days 35 and 43 post-
implantation compared to day 7. Error bars are S.E.M..
doi:10.1371/journal.pone.0073138.g004
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nance as an episome [33]. Unfortunately, these first generation S/
MAR plasmids had two main drawbacks. First, the requirement
for antibiotic selection to establish these vectors as replicating
episomes violates regulatory ‘‘plasmids free of antibiotic resistance
genes’’ (pFAR) principles [15,34]. In addition, further investiga-
tion of S/MAR plasmids revealed that in some clonal cell
populations these vectors can eventually integrate into the genome
after long periods of time in culture, and therefore would not be
pursued clinically [14]. In recent years this has led to removal of
prokaryotic components and development of S/MAR MCs [14–
16]. Compared to S/MAR plasmids, S/MAR MCs have several
important safety advantages related to their eventual translation
into humans; they do not require antibiotic selection to become
established as episomes and also have a greater tendency to resist
integration [14,15]. Importantly, we have demonstrated in this
study that S/MAR MCs can be used as a vector platform to label
cells with RGs and track the proliferation and viability of
transplanted cells in living subjects.
Recently, Argyros et al demonstrated the ability to label cancer
cells with S/MAR ‘‘plasmids’’ for the purposes of developing
imageable tumor models without the need to modify the cancer
cell’s genome [35]. In their study, the S/MAR plasmids were
driven by the mammalian Ubiquitin C promoter, expressed firefly
luciferase, and contained the hIFN-ß S/MAR. Two different types
of cancer cell types were labeled and the ability to monitor cancer
progression in mice with bioluminescence imaging was demon-
strated. Our work supports the notion of using S/MAR vectors for
monitoring tumor development in mice without the need to
modify the cancer cell genome. We observed differences in the
absolute amount of luciferase signal in cells transfected with either
S/MAR PPs and S/MAR MCs (Figure 2A). Several reasons can
explain these differences. Firstly, we transfected cells with equal
mass of both PP and MC, therefore a greater number of
transcription units were transfected using S/MAR MCs. Another
partial explanation could be that without selection pressure S/
MAR MCs are known to replicate whereas S/MAR PPs do not
[14]. Another reason could be that there could be slightly more
cells in the MC plate than the PP plate, however we did not see
any obvious qualitative differences in cell number. Due to the
different sizes of the constructs it would be difficult to assess
absolute transfection efficiency without including another reporter
within the construct itself. We did not pursue this strategy since it
has been described previously [14,15], and in our own experienc-
es, that S/MAR constructs have a maximum cloning capacity, and
therefore we wanted to minimize the overall size of our constructs.
Critically, we believe S/MAR MCs will have significant advan-
tages over S/MAR plasmids as we move towards our intended
purpose: translation of these vectors for tracking therapeutic cells
in patients with clinically relevant RGs. Safety will be of utmost
importance for translation and as described above, S/MAR MCs
have clear advantages over S/MAR plasmids regarding safety
concerns.
Another advantage of our particular MC construct is that while
our initial goal was to label cells indefinitely as has been previously
described with other MC constructs [14–16,35], serendipitously
across several clonal cell populations we saw a consistent slow drift
towards lower Fluc activity (Figure 3A) and S/MAR MC content
over time (Figure 3B). To explain these findings, it has been
previously shown that the ability of S/MAR vectors to replicate is
dependent on ongoing transcription into the S/MAR motif [36].
Therefore, our theory for the loss of RG expression and vector
over time relates to the selective use of the CMV promoter
(pCMV) in our MC constructs. Studies have shown that loss of
gene expression due to silencing is promoter-dependent [37], and
that the CMV promoter is particularly prone to CpG methylation-
based silencing both in vitro and in vivo [16,38,39]. In our case, the
silencing of pCMV would result in a gradual inhibition of RG
transcription, inhibition of the ability of the MC to replicate, and
as those cells continue to divide the non-replicative MC would
eventually be lost. This provides an exciting way to reversibly
modify cells with RGs after a prolonged imaging window (months),
and is even safer and may have many more specific applications in
the clinic compared to a system that modifies cells indefinitely.
Future work will focus on development of MC constructs that
utilize mammalian promoters, such as the Ubiquitin C promoter
[35], that do not easily get silenced to cover applications that
require longer cell imaging windows and, as has been recently
explored [40], the use of inducible promoters that can be turned
off once the appropriate imaging window has been achieved.
One of the limitations of our current generation of S/MAR
MCs is the use of the 2.2 kb hIFN-ß S/MAR motif. In an detailed
study by Broll and colleagues using MC constructs containing this
S/MAR, a few clonal populations expanded after FAC sorting
showed evidence of eventual integration after long periods in
culture (5 months) [15]. Of note though, this same study described
a shorter S/MAR motif (733 bp) called M18, identified after in vivo
recombination in one of their clonal populations, that when
incorporated into MC constructs showed largely improved cloning
capacity and stability [15]. Another limitation of S/MAR vectors
in general is the low establishment rate within cells; with S/MAR
MCs it is estimated that the final rate of establishment is less than 5
percent [15]. This appears to be regulated at the epigenetic level,
since treatment of cells prior to transfection with histone deactylase
(HDAC) inhibitors, such as butyrate, to open up the cell’s
chromatin structure can improve the establishment rate [15].
Continued work exploring the effects of other HDAC inhibitors or
other epigenetic factors that can be modulated to improve
establishment rates are warranted.
To our knowledge, this is the first work exploring the use of
replicating, self-limited episomal MCs to monitor cell proliferation
and viability in living subjects. S/MAR MCs are a promising non-
integrative, replicative vector platform that avoids the safety issues
of integrative technologies but provides an imaging window (.3
months) that would allow clinicians to monitor cell fate early in the
treatment process and, if needed, intervene in a timely fashion.
This work was supported by
Supporting Information
Figure S1 Proliferation of S/MAR MC labeled cells can
be monitored over time in living subjects. S/MAR MC
labeled breast cancer cells were implanted into the right flank of
Nu/Nu mice and bioluminescence imaging (BLI) was performed
over time. As tumors developed more luminescent signal was
noted.
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